The Introduction of H₂-Receptor Antagonists to Scandinavia: Effects of Experts' Opinions

References

• Molinder H. Scandinavian views on non surgical treatment of peptic ulcer. Scand J Gastroenterol 1995; 30: 721–30.
   PubMed Web of Science ®Google Scholar
• Black J, Duncan A, Durant C, Ganellin C, Parsons E. Defintion and antagonism of histamine H₂-receptors. Nature 1972; 236: 385–90.
   Google Scholar
• Adami H-O, Agenäs I, Gustavsson S, Lööf L, Nyberg A, Nyrén O, et al. The clinical diagnosis of ‘gastritis’. Scand J Gastroenterol 1984; 19: 216–9.
   PubMed Web of Science ®Google Scholar
• Danish Drug Catalogue. Copenhagen: Dansk Laegemiddelsin-formation AS; 1977, 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985.
   Google Scholar
• The Norwegian Pharmaceutical Product Compendium. Oslo: Elander’s Publishing AS; 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985.
   Google Scholar
• Swedish Drug Compendium. Stockholm: Läkemedelsinformation AB; 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985.
   Google Scholar
• Rune S, Wulff H. Cimetidin—en histamin receptor antagonist. (Cimetidine—an H₂-receptor antagonist). Ugeskr Laeger 1977; 139: 593–5.
   PubMedGoogle Scholar
• Bodemar G, Walan A. Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet 1976; 2: 161–4.
   PubMed Web of Science ®Google Scholar
• Semb L, Berstad A, Myren J, Foss J, Carlsen E, Kruse-Jensen A. A double blind multicenter comparative study of cimetidine and placebo in short-term treatment of active duodenal ulceration. In: Burland W, Simkins M, editors. Second international symposium on histamine-receptor antagonists. London: Excerpta Medica; 1976. p. 248–53.
   Google Scholar
• Gudmand-Höyer G, Frost F, Jensen K, Krag E, Rask-Madsen J, Rahbek I, et al. A pragmatic trial of cimetidine in duodenal ulcer patients. Scand J Gastroenterol 1977; 12: 611–3.
   Google Scholar
• Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978; 1: 403–7.
   PubMed Web of Science ®Google Scholar
• Gudmand-Höyer E, Jensen KB, Krag E, Rask-Madsen J, Rahbek I, Rune SJ, et al. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1978; 1: 1095–7.
   Google Scholar
• Berstad A, Aadland E, Carlsen E, Myren J, Semb L, Kruse-Jensen A. Maintenance treatment of duodenal ulcer patients with a single bedtime dose of cimetidine. Scand J Gastroenterol 1979; 14: 827–31.
   Google Scholar
• Discussion. Medicinsk behandling av ulcussjukdomen. (Medical treatment of peptic ulcer disease.). In: Hässle, editor. Ulcus og ulcusbehandling. Gothenburg: Hässle; 1976. p. 145–60.
   Google Scholar
• Walan A. Medicinsk behandling av ulcussjukdomen. (Medical treatment of peptic ulcer disease.). In: Forsell H, Walan A, editors. Sjukdomar i ovre gastrointestinalkanalen. Gothenburg: Hässle; 1979. p. 93–107.
   Google Scholar
• Järhult B. Tagamet från ditriktsläkarens utmarker. (Tagamet from a district physician’s wilderness.). Lakartidningen 1978; 75: 3533–4.
   Google Scholar
• Dotevall G. Behandling med cimetidin vid magsårssjukdomen. (Cimetidine therapy in case of gastric ulcer. English summary.). Lakartidningen 1979; 76: 719–22.
   Google Scholar
• Wulff H. Cimetidinbehandling af ulcuspatienter. (Treatment of peptic ulcer patients with cimetdine.). Month J Clin Pract 1978; 3: 125–34.
   Google Scholar
• Alván G, Gustafsson L, Öhman B. Biverkningar av cimetidin— dagsläget. (Side effects of cimetidine—the actual situation.). Lakartidningen 1979; 76: 2767–8.
   Google Scholar
• Discussion. Peptic ulcer disease and its treatment. Scand J Gastroenterol 1979; 14 Suppl 55: 77–83, 114–6.
   Google Scholar
• Berstad A. Cimetidin. Tidsskr Nor Legeforen 1979; 99: 1334–7.
   Google Scholar
• Bodemar G, Gotthard R, Larsson R, Norlander B, Ström M, Walan A. Cimetidin—mest positiva erfarenheter efter fem år. (Cimetidine—mostly positive experiences after five years.). Lakartidningen 1981; 78: 2300–4.
   Google Scholar
• Bodemar G. Long term use of cimetidine in the treatment of peptic ulcers: clincal considerations. Intern Med Spec 1983; 4: 68–81.
   Google Scholar
• Bodemar G, Walan A. Two-year follow up after one year’s treatment with cimetidine or placebo. Lancet 1980; 1: 38.
   PubMedGoogle Scholar
• Walan A, Bianchi-Porro G, Hentschel K, Bardhan E, Delattre M. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397–405.
   PubMed Web of Science ®Google Scholar
• Ström M, Bodemar G, Lindhagen J, Sjödahl R, Walan A. Cimetidine or parietal-cell vagotomy in patients with juxtapyloric ulcers. Lancet 1984; 2: 894–7.
   Google Scholar
• Bodemar G. När är ulcuskirurgi fortfarande indicerad? Medicinarens synpunkter. (When is surgery still indicated? The views of an internist.). Opmear 1982; 27: 10–5.
   Google Scholar
• Walan A, Ström M. Prevention of ulcer recurrence. Medical vs surgical treatment. The physician’s view. Scand J Gastroenterol 1985; 20 Suppl 110: 83–8.
   Google Scholar
• Dahlgren G. Magsårskirurgi—en medicinhistorisk parentes? (Ulcus surgery—a parenthesis in medical history?). Lakartidningen 1991; 88: 3827–30.
   PubMedGoogle Scholar
• Amdrup E. Surgery is preferable in patients with severe chronic peptic ulcer disease. Scand J Gastroentrol 1988; 23 Suppl 155: 155–8.
   Google Scholar
• Gustavsson S, Nyrén O. Stadig minskning av operationer för ventrikel-och duodenalsår. (Steady decrease of surgery for gastric and duodenal ulcer.) Lakartidningen 1989; 40: 3357–61.
   Google Scholar
• Haglund U, Oscarson J. Kirurgi förstahandalternativ vid okomplicerad ulcus duodeni-sjukdom. (Surgery first line treatment at uncomplicated duodenal ulcer disease.) Lakartidningen 1986; 83: 193–4.
   Google Scholar
• Ström M. Comparison between medical and elective surgical treatment of peptic ulcers. Scand J Gastroenterol 1988; 23 Suppl 155: 159–62.
   Google Scholar
• Gustavsson S. Peptic ulcer disease-trends in surgical managemantin Sweden. Scand J Gastroenterol 1988; 23 Suppl 155: 152–4.
   Google Scholar
• Ganellin C, Parsons M Pharmacology of histamine-receptors. Bristol: Wright PSG; 1982.
   Google Scholar
• Gifford L, Aeugle M, Myerson R, Tannenbaum P. Cimetidine postmarket surveillance program. JAMA 1980; 243: 1532–5.
   PubMed Web of Science ®Google Scholar
• Trang L. Översikt över biverkningar i relation till H2-blockad. (Review over side effects related to H₂-blockade.). Opmear 1982; 27: 66–70.
   Google Scholar
• Penston J, Wormsley K. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol 1986; 1: 192–216.
   PubMedGoogle Scholar
• Bardhan K. Six years of continuous cimetidine treatment in peptic ulcer disease: efficacy and safety. Aliment Pharmacol Ther 1988; 2: 395–405.
   PubMed Web of Science ®Google Scholar
• Colin-Jones D, Langman M, Lawson D, Logan R, Paterson K, Vessey M. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992; 33: 1280–4.
   Google Scholar
• Burland W. Evidence for the safety of cimetidine in the treatment of peptic ulcer disease. In: Creutzfeldt W, editor. International Symposium on Histamine H2-receptor Antagonists. Amsterdam: Excerpta Medica; 1977. p. 238–58.
   Google Scholar
• Järhult B. Eraldina—och sedan Tagamet? (Eraldina—and then Tagamet?) Lakartidningen 1978; 75: 4589–91.
   Google Scholar
• Forrest J. Neutropenia associated with metiamide. Lancet 1975; 1: 392–3.
   PubMedGoogle Scholar
• Burland W. Reversal of metiamide-induced agranulocytosis during treatment with cimetidine. Lancet 1975; 2: 1085.
   PubMedGoogle Scholar
• Brimblecombe R. Cimetidine and the possible formation of Nnitroso compounds. In: Baron J, editor. Cimetidine in the 80s. London: Churchill Livingstone; 1981. p. 353–60.
   Google Scholar
• Elder J, Ganguli P, Gillespie I. Cimetidine and gastric cancer. Lancet 1979; 1: 1005–6.
   Google Scholar
• Möller H, Lindvig K, Klefter R, Mosbech J, Jensen OM. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1588–62.
   Google Scholar
• Wormsley K. Assessing the safety of drugs for the long-term treatment of peptic ulcers. Gut 1984; 25: 1416–23.
   PubMed Web of Science ®Google Scholar
• Colin-Jones D, Langman M, Lawson D, Logan R, Paterson K, Vessey M. Post-cimetidine surveillance for up to ten years: Incidence of carcinoma of the stomach and oesophagus. Q J Med 1991; 78: 13–9.
   Google Scholar
• Aadland E, Berstad A. Parietal and chief cell sensitivity to pentagastrin stimulation before and after cimetidine treatment for duodenal ulcer. Scand J Gastroenterol 1979; 14: 11–4.
   Google Scholar
• Aadland E, Berstad A, Granerus G. Effect of cimetidine treatment on parietal and chief cell sensitivity to histamine and or catabolism of histamine in duodenal ulcerpatients. Scand J Gastroenterol 1980; 15: 749–54.
   Google Scholar
• Bodemar G, Norlander B, Walan A, Larsson R. Short and longterm treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine. Scand J Gastroenterol 1979; 14 Suppl 55: 96–106.
   Google Scholar
• Spence R, Celestin L, McCormic D, Owens C, Oliver J. The effect of long-term treatment with cimetidine on gastric secretion and gastrin responses in man. In: Creutzfeldt W, editor. International Symposium on Histamine H2-Receptor Antagonists. Amsterdam: Excerpta Medica; 1977. p. 116–34.
   Google Scholar
• Frislid K, Aadland E, Berstad A. Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects. Scand J Gastroenterol 1986; 21: 119–22.
   Google Scholar
• Jones D, Howden C, Burget D, Silletti S, Hunt R. Alteration on H2-receptor sensitivity in duodenal ulcer patients after maintenence treatment with an H₂-receptor antagonist. Gut 1988; 29: 890–93.
   Google Scholar
• Ippoliti A, Elashoff J, Valenzuela J, Cano R, Frankl H, Samloff M, et al. Recurrent ulcer after successful treatment with cimetidine or antacid. Gastroenterology 1983; 85: 875–80.
   PubMed Web of Science ®Google Scholar
• Becker U, Lindorff K, Andersen C, Ranlöv P. Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221: 95–101.
   PubMed Web of Science ®Google Scholar
• Hentschel E, Schuetze K, Dufek W. Relapse rate of duodenal ulcer healed with concentrated antacid or cimetidine. Hepato-gastroenterology 1984; 31: 266–8.
   Google Scholar
• Jönsson K-Å, Bodemar G, Norrby K, Walan A, Tysk C, Darle N, et al. Are endoscopic and/or histologic findings in gastroduodenal mucosa a predictor of clinical outcome in peptic ulcer disease? Scand J Gastroenterol 1988; 23: 199–208.
   Google Scholar
• Ström M, Gotthard R, Bodemar G. Antacid/anticholinergic, cimetidine and placebo in treatment of active peptic ulcers. Scand J Gastroenterol 1981; 16: 593–602.
   Google Scholar
• Marks I, Wright J, Lucke W, Girdwood A. Relapse rates following initial healing with sucralfate and cimetidine. Scand J Gastroenterol 1982; 17: 429–32.
   PubMed Web of Science ®Google Scholar
• Lam S, Hui W, Lau W, Branicki FJ, Lai CL, Lok ASF, et al. Sucralfate overcomes adverse effect of cigarrette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology 1987; 92: 1193–201.
   PubMed Web of Science ®Google Scholar
• Hallerbäck B, Solhaug J-H, Carling L, Glise H, Hallgren T, Kagevi I, et al. Recurrent ulcer after treatment with cimetidine or sucralfate. Scand J Gastroenterol 1987; 22: 791–7.
   Google Scholar
• Kang J, Piper D. Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Digestion 1982; 23: 73–9.
   PubMed Web of Science ®Google Scholar
• Martin D, Hollanders D, May S, Ravenscroft M, Tweedle D, Miller J. Difference in relapse rate of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; 1: 7–10.
   PubMed Web of Science ®Google Scholar
• Cipollini F, Altilia F. Comparison of tri-potassium di-citrato bismuthte (TDB) with ranitidine in healing and relapse of gastric ulcer. Br J Clin Pract 1987; 41: 707–9.
   PubMedGoogle Scholar
• Lee F, Samloff I, Hardman M. Comparison of tri-potassium dicitrato bismuthate with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299–302.
   Google Scholar
• Bodemar G. Does the choice of acute treatment influence future ulcer relapse? Scand J Gastroenterol 1988; 23 Suppl 155: 141–51.
   Google Scholar
• Dobrilla G, Vallaperta P, Amplatz S. Influence of ulcer healing agents on ulcer relapse rate after discontinuation of acute treatment: a pooled estimate of controlled trials. Gut 1988; 29: 181–7.
   Google Scholar
• Adami H, Björklund O, Enander L-K, Gustavsson S, Lööf L, Nordahl A, et al. Klinisk misstanke eller endoskopi som underlag för cimetidinterapi vid ulcus? (Clinical suspicion or endoscopy as a base for treatment in peptic ulcer?). Lakar-tidningen 1981; 78: 319.
   Google Scholar
• Walan A, Gustavsson S. Skärpt diagnostik krävs vid behandling av magsår och magbesvär. (More stringent diagnoses are demanded at treatment of peptic ulcer and abdominal complaints.). Lakartidningen 1985; 42: 3587–8.
   Google Scholar
• Colin-Jones D. Management of dyspepsia. Report of a working party. Lancet 1988; 1: 576–9.
   PubMed Web of Science ®Google Scholar
• Crean G, Bodemar G, Howden C. Controversies in dyspepsia: cost containment. Gastroenterol Today 1991; 1: 62–5.
   Google Scholar
• Johannessen T. Skal pasienter med dyspepsi endoskoperas eller provebehandles? (Endoscopy or trial treatment of dyspepsia? English summary.) Nord Med 1989; 104: 18–20.
   PubMedGoogle Scholar
• Järhult J, Ulgemo A. Normalt gastroskopifynd inget hinder för syrahämmande läkemedel vid dyspepsi. (Normal endoscopic findings no hinder for acid inhibiting drugs in dyspepsia.) Lakartidningen 1991; 88: 4003–4.
   Google Scholar
• Jönsson B. Nytt läkemedel gav vinst för samhället trots ökade kostnader inom sjukvården. (New drug caused gain to the society in spite of increased costs within health care.) Lakartidningen 1983; 80: 1165–7.
   Google Scholar
• Christensen A, Bousfield R. Ulcuskirurgi for og efter indforelsen af H2-blokkerbehandlingen. (Ulcer surgery before and after the introduction of treatment with H₂-blockers.) Ugeskr Laeger 1987; 149: 2895–7.
   Google Scholar
• Haaverstad R, Moen O, Kannelonning S, Line P-D, Wibe A, Bjerkeset T. Ulcuskirurgi og ulcusmidler (Surgical and medical treatment for peptic ulcer in Nord-Tröndelag 1975–89. English summary.) TidsskrNor Laegeforen 1994; 114: 904–7.
   Google Scholar
• Möller-Hansen J, Bytzer P, Muckadell OSd. Sundhetsekonomiske aspekter av nyere ulcusmedicin. (Social-economical aspects of medication for peptic ulceration. English summary.) Ugeskr Laeger 1992; 154: 1687–90.
   Google Scholar
• Farbrot T, Farbrot E. Effekt av cimetidinbehandling på sykmelding og hospitalisering. (Effect of treatment with cimetidine on sick leave and hospitalisation.) Tidsskr Nor Laegeforen 1984; 194: 595–6.
   Google Scholar
• Jönsson B, Carlsson P. The effects of cimetidine on the cost of ulcer disease in Sweden. Soc Sci Med 1991; 33: 275–82.
   PubMed Web of Science ®Google Scholar
• Tyllström J, Adami HO, Agenäs I, Gustavsson S, Lööf L, Nyberg A, et al. The clinical diagnosis of gastritis. Scand J Gastroenterol 1984; 19: 755–60.
   PubMed Web of Science ®Google Scholar